Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a genetic condition predisposing individuals to the development of benign and malignant tumors across various organs. This review explores the intricate genetic underpinnings of VHL disease, its clinical manifestations, and the associated malignancy risks. The latest diagnostic criteria, surveillance guidelines, and advancements in therapeutic strategies, including the Food and Drug Administration-approved hypoxia-inducible factor-2α inhibitor, belzutifan, are focused on. Through a multidisciplinary approach, tailored surveillance programs aim to improve patient outcomes while balancing intervention risks. Emerging technologies such as wholebody magnetic resonance imaging and liquid biopsies hold promises for enhancing non-invasive surveillance. This review underscores the significance of ongoing research and interdisciplinary care in managing this complex syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 3×
“Additionally, the HIF-2α inhibitor belzutifan has shown promising anti-tumor activity, including stabilizing disease and reducing progression rates 18,47,88) .”
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305 · cited 2×
“Additionally, the HIF-2α inhibitor belzutifan has shown promising anti-tumor activity, including stabilizing disease and reducing progression rates 18,47,88) .”
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1054 · Cited by 180 · cited 1×
“For example, the HIF 2-alpha (HIF-2α) inhibitor, Belzutifan, has been approved by the US Food and Drug Administration in 2021 for treating CNS HB, retinal HB, and RCC associated with VHL disease, particularly in patients who do not require immediate surgical intervention 18,25,28,47,125) .”
Research works printed but not linked: 121
- 10.1002/jcu.1870190715 · doi:10.1002/jcu.1870190715
- 10.3171/jns.2006.105.2.248 · DOI · Paper page
- 10.15586/jkcvhl.2015.41 · DOI
- 10.1093/neuonc/nop018 · DOI
- Atuk, 1979, Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease. A ten year study of a large family, 209
- 10.1002/hed.24067 · doi:10.1002/hed.24067
- Bickler, 1984, Pancreatic involvement in Hippel-Lindau disease, 280
- Binderup, 2013, Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition, B4763
- 10.1212/wnl.0000000000002064 · doi:10.1212/wnl.0000000000002064
- 10.1136/jmedgenet-2016-104058 · DOI · Paper page
- 10.1136/jnnp.53.8.644 · doi:10.1136/jnnp.53.8.644
- 10.1007/s11060-019-03213-z · doi:10.1007/s11060-019-03213-z
- 10.1097/ju.0000000000001912 · DOI · Paper page
- Chang, 1998, Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery, 28
- 10.1002/humu.1380050109 · DOI · Paper page
- 10.1016/b978-0-444-62702-5.00010-x · DOI · Paper page
- 10.3171/jns.2004.100.3.0480 · doi:10.3171/jns.2004.100.3.0480
- 10.1148/radiology.194.3.7862955 · DOI · Paper page
- 10.1016/j.jmoldx.2019.01.005 · doi:10.1016/j.jmoldx.2019.01.005
- 10.1093/hmg/3.8.1303 · DOI · Paper page
- 10.1002/cncr.34896 · DOI · Paper page
- 10.1227/00006123-198911000-00002 · doi:10.1227/00006123-198911000-00002
- de Tersant, 2020, Pheochromocytoma and paraganglioma in children and adolescents: experience of the French Society of Pediatric Oncology (SFCE), bvaa039
- 10.2217/cns-2022-0008 · DOI
- 10.1001/jamaneurol.2017.4469 · DOI
- 10.1210/js.2019-00225 · DOI
- 10.1093/neuonc/nov313 · DOI
- 10.1212/wnl.41.1.41 · doi:10.1212/wnl.41.1.41
- 10.3390/genes12091414 · DOI
- 10.1148/rg.2018184005 · DOI
- Goldberg, 1974, Argon laser treatment of von Hippel-Lindau retinal angiomas. I. Clinical and angiographic findings, 121
- 10.1016/s0161-6420(92)32024-x · DOI
- 10.1007/s00345-019-02650-9 · doi:10.1007/s00345-019-02650-9
- 10.1016/s0161-6420(84)34304-4 · doi:10.1016/s0161-6420(84)34304-4
- 10.1007/s00330-012-2636-6 · DOI
- 10.1016/s0300-2977(01)00165-6 · doi:10.1016/s0300-2977(01)00165-6
- 10.1001/archinte.1976.03630070017007 · doi:10.1001/archinte.1976.03630070017007
- Hull, 1986, Phaeochromocytoma. Diagnosis, preoperative preparation and anaesthetic management, 1453
- 10.1227/neu.0000000000000384 · doi:10.1227/neu.0000000000000384
- 10.3171/2015.1.jns131963 · doi:10.3171/2015.1.jns131963
- 10.3171/2021.3.jns204203 · doi:10.3171/2021.3.jns204203
- 10.3171/2015.4.jns1533 · doi:10.3171/2015.4.jns1533
- 10.1016/s1470-2045(24)00389-9 · DOI · Paper page
- 10.3171/jns/2008/108/2/0210 · DOI
- 10.1007/s00701-012-1514-y · doi:10.1007/s00701-012-1514-y
- 10.3171/2014.10.jns131602 · doi:10.3171/2014.10.jns131602
- 10.1016/0002-9343(94)90026-4 · doi:10.1016/0002-9343(94)90026-4
- 10.3171/jns.2005.102.3.0503 · doi:10.3171/jns.2005.102.3.0503
- 10.1002/lary.23646 · DOI
- Knudson, 1985, Hereditary cancer, oncogenes, and antioncogenes, 1437
- Kragel, 1991, Simple renal cysts, atypical renal cysts, and renal cell carcinoma in von Hippel-Lindau disease: a lectin and immunohistochemical study in six patients, 210
- 10.1016/j.ophtha.2006.02.059 · doi:10.1016/j.ophtha.2006.02.059
- 10.1530/erc-13-0308 · DOI
- 10.1002/cncr.33978 · DOI · Paper page
- 10.1097/00005792-198901000-00001 · DOI · Paper page
- 10.1097/mou.0000000000000950 · DOI
- Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, 1317
- 10.1067/msy.2000.110239 · DOI
- 10.1007/s11060-019-03118-x · doi:10.1007/s11060-019-03118-x
- Lindau, 1926, Studien uber kleinhirncysten. Bau, pathogenese und beziehungen zur angiomatosis retinae, 1
- 10.3171/2014.1.jns131431 · DOI · Paper page
- 10.1016/s0140-6736(03)13643-4 · DOI · Paper page
- 10.3171/jns.2003.98.1.0106 · doi:10.3171/jns.2003.98.1.0106
- 10.1136/jmg.33.2.120 · DOI · Paper page
- 10.1136/bmj.307.6899.279 · doi:10.1136/bmj.307.6899.279
- 10.1136/jmg.28.7.443 · DOI · Paper page
- 10.1038/ejhg.2010.175 · DOI · Paper page
- 10.3109/13816819509059966 · DOI
- 10.1093/qjmed/77.2.1151 · DOI · Paper page
- 10.1001/jama.1997.03540420057030 · DOI · Paper page
- 10.1016/0749-2081(92)90041-z · doi:10.1016/0749-2081(92)90041-z
- 10.1038/20459 · DOI · Paper page
- Melmon, 1964, Lindau’s disease. Review of the literature and study of a large kindred, 595
- 10.1177/1753495x16683088 · doi:10.1177/1753495x16683088
- 10.3390/cancers14215313 · DOI
- Neumann, 1987, Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome, 220
- Neumann, 1987, Prognosis of von Hippel-Lindau syndrome, 309
- 10.1016/s0022-5347(01)62509-6 · DOI · Paper page
- 10.1016/0016-5085(91)90026-h · DOI · Paper page
- 10.1111/j.1750-3639.1995.tb00592.x · DOI
- 10.1016/0140-6736(91)91705-y · DOI · Paper page
- 10.1200/jco.2015.65.6140 · DOI · Paper page
- 10.1007/s007010050412 · doi:10.1007/s007010050412
- 10.1016/j.jocn.2024.110774 · DOI
- 10.1007/s11060-017-2697-0 · DOI
- 10.1097/00007890-199304000-00011 · DOI · Paper page
- 10.1016/j.clineuro.2020.105912 · DOI
- 10.1158/1078-0432.ccr-17-0547 · DOI · Paper page
- Richard, 1998, von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management, 258
- Ridley, 1986, Retinal angiomatosis: the ocular manifestations of von Hippel-Lindau disease, 276
- 10.1097/00129492-200407000-00030 · doi:10.1097/00129492-200407000-00030
- 10.1001/jama.2024.12848 · DOI · Paper page
- Seitz, 1987, von Hippel-Lindau disease in an adolescent, 632
- Seizinger, 1989, Fundamental mechanisms of tumorigenesis in the human nervous system: isolation and characterization of genes associated with hereditary forms of cancer, B25
- 10.1038/332268a0 · DOI · Paper page
- 10.1073/pnas.88.7.2864 · doi:10.1073/pnas.88.7.2864
- 10.1097/mpa.0000000000000875 · DOI
- 10.1016/s0161-6420(01)00758-8 · doi:10.1016/s0161-6420(01)00758-8
- 10.1002/ajmg.a.33407 · doi:10.1002/ajmg.a.33407
- 10.1016/s0022-5347(01)67318-x · doi:10.1016/s0022-5347(01)67318-x
- 10.1002/(sici)1098-1004(1998)12:6<417::aid-humu8>3.3.co;2-b · doi:10.1002/(sici)1098-1004(1998)12:6<417::aid-humu8>3.3.co;2-b
- 10.1002/1097-0142(19820201)49:3<553::aid-cncr2820490326>3.0.co;2-a · doi:10.1002/1097-0142(19820201)49:3<553::aid-cncr2820490326>3.0.co;2-a
- 10.1093/jnci/81.14.1097 · doi:10.1093/jnci/81.14.1097
- 10.1186/s13053-019-0121-9 · DOI
- 10.15586/jkcvhl.2017.88 · DOI · Paper page
- 10.1007/bf01994821 · DOI · Paper page
- 10.3390/genes15070905 · doi:10.3390/genes15070905
- 10.1016/s0022-5347(01)61900-1 · DOI · Paper page
- 10.1016/s0022-5347(01)66674-6 · DOI · Paper page
- 10.3171/jns.2003.98.1.0095 · DOI · Paper page
- Whaley, 1994, Germline mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma, 1092
- 10.3171/2010.9.jns10839 · doi:10.3171/2010.9.jns10839
- 10.1586/ern.11.124 · doi:10.1586/ern.11.124
- 10.1016/s0161-6420(81)34858-1 · doi:10.1016/s0161-6420(81)34858-1
- 10.1046/j.1365-2796.1998.00338.x · doi:10.1046/j.1365-2796.1998.00338.x
- 10.1016/s0022-5347(17)49380-3 · doi:10.1016/s0022-5347(17)49380-3
- 10.1002/cncr.34265 · DOI · Paper page
- 10.1016/j.ophtha.2007.03.009 · doi:10.1016/j.ophtha.2007.03.009
- 10.1016/j.jocn.2017.05.029 · doi:10.1016/j.jocn.2017.05.029
- Yucha, 1991, Pheochromocytoma. The great mimic, 136
- 10.1007/s11060-023-04496-z · DOI
Metadata
- Authors
- Jung, N. Y., & Park, J. B.
- Venue
- Journal of Korean Neurosurgical Society
- Publisher
- Korean Neurosurgical Society
- Published
- 2025-05-01
- Volume
- 68
- Issue
- 3
- Pages
- 338-349
- ISSN
- 2005-3711
- 1598-7876
- Cited by
- 8
- References
- 4
- Language
- en
- Update notices
- correction (2025-06-18)
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance. https://app.cochat.ai/papers/10.3340/jkns.2025.0018
- The paper
- Jung, N. Y., & Park, J. B. (2025). Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance. Journal of Korean Neurosurgical Society. https://doi.org/10.3340/jkns.2025.0018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.